Phase I Study of MK-3475 (Pembrolizumab) in Patients with Human Immunodeficiency Virus (HIV) and Relapsed/Refractory or Disseminated Malignant Neoplasm

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Hiv And Relapsed Or Refractory Or Disseminated Malignant Neoplasm
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:

    1.  Patients must have histologically or cytologically proven metastatic or locally advanced tumors for which no standard therapy exists, or where standard therapy has failed


    2.  Patients must have at least 2 weeks from end of chemotherapy with resolution of neutropenia to above level


    3.  Patients must have CD4+ T-cell count greater than or equal to 100 cells/microliter; for CD4+ T-cell count <200 cells/microliter, requires CD4+/CD8+ T-cell ratio greater than 0.4

You may not be eligible for this study if the following are true:

  • 1.  Patients with active systemic immunosuppressive therapy


    2.  Systemic steroid therapy or steroid therapy that cannot be discontinued with more than 7 consecutive days of steroids within the prior 2 weeks


    3.  Patients with current or history of systemic autoimmune disease requiring systemic therapy


    4.  Patients with uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia


If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.